CWY

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, March 14, 2023
Research, Experiment, Book, FSE, Bangladesh Technical Education Board, Addiction medicine, U.S. News & World Report, News, Genetics, CSE, Nicotine, CWY, Alcoholism: Clinical and Experimental Research, SAB, Benjamin Rush, Coronavirus Scientific Advisory Board, Therapy, University, Pharmaceutical industry, Addiction

Tel Aviv, Israel / Vancouver, Canada, March 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the appointment of Professor Henry R. Kranzler, M.D., as the newest member of its Scientific Advisory Board ("SAB").

Key Points: 
  • Professor Kranzler is the Benjamin Rush Professor of Psychiatry, and Director of the Center for Studies of Addiction, at the University of Pennsylvania’s Perelman School of Medicine, which was ranked #6 in 2023 on the US News & World Report rankings.
  • His research focuses on the genetics and pharmacological treatment of substance dependence, with emphasis on precision addiction medicine.
  • “We are honored to have a world-renowned figure like Professor Kranzler join our SAB alongside other prestigious professionals," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.
  • “Professor Kranzler is an expert on addiction medicine, especially genetic and pharmacological aspects of alcohol and other substance use disorders, aligning perfectly with Clearmind's mission.

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

Retrieved on: 
Wednesday, February 22, 2023
Safety, Doctor of Philosophy, Central nervous system, FSE, CSE, DSM-IV codes, Patient, CWY, MDMA, Patent, Lysergic acid diethylamide, N, Psilocybin, Therapy, PEA, United States Patent and Trademark Office, Obesity, Pharmaceutical industry, Ibogaine, Ketamine

Tel Aviv, Israel / Vancouver, Canada, Feb. 22, 2023 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psychedelic-based compounds,  as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"),  a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to novel proprietary combinations of 3,4-Methyl​enedioxy​methamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.
  • "We are proud to be leaders in the psychedelic industry with the most robust IP portfolio consisting of granted and pending patents.
  • We plan to continue to be pioneers in the field of novel psychedelic compounds and treatments."
  • Clearmind has a broad IP footprint in the psychedelic space, with 29 patents in 13 patent families, of which 9 have been granted in major jurisdictions like the US, Europe, China, and India.

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

Retrieved on: 
Wednesday, February 22, 2023
Central nervous system, FSE, CSE, DSM-IV codes, CWY, Patent, Lysergic acid diethylamide, N, Psilocybin, Therapy, United States Patent and Trademark Office, Obesity, Pharmaceutical industry

Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psychedelic-based compounds.

Key Points: 
  • Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psychedelic-based compounds.
  • Overall, as part of this collaboration, six other patent applications have been filed by Clearmind with the USPTO for various combinations, three of them for the combination of SciSparc’s  PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders, and recently for novel proprietary combinations of lysergic acid diethylamide (“LSD”), psilocybin, and N,N-dimethyltryptamine (“DMT”) and SciSparc’s PEA, the active ingredient of its proprietary CannAmide™.
  • As part of the collaboration agreement, any assets generated from the collaboration will belong to both companies.

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

Retrieved on: 
Wednesday, February 15, 2023
Patent, PEA, Lysergic acid diethylamide, CWY, Therapy, United States Patent and Trademark Office, MEAI, Safety, Obesity, Patient, LSD, Psilocybin, DMT, FSE, Central nervous system, DSM-IV codes, CSE, Doctor of Philosophy, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO) as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc").

Key Points: 
  • The patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™.
  • SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
  • Clearmind has a broad IP footprint in the psychedelic space with 23 patents in seven patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

Retrieved on: 
Wednesday, February 15, 2023
TEL, Patent, PEA, Lysergic acid diethylamide, CWY, Therapy, United States Patent and Trademark Office, Safety, Obesity, Psilocybin, FSE, Central nervous system, DSM-IV codes, CSE, Pharmaceutical industry

TEL AVIV, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, three provisional patent applications were filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).

Key Points: 
  • The patent applications refer to novel proprietary combinations of lysergic acid diethylamide (“LSD”), psilocybin, and N,N-dimethyltryptamine (“DMT”) and SciSparc’s Palmitoylethanolamide (“PEA”), the active ingredient of its proprietary CannAmide™.
  • Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders.
  • “These new patent applications continue to support our findings of the major role CannAmideTM, our proprietary PEA formulation, plays in SciSparc’s various proprietary combination treatments,” said Oz Adler, Chief Executive Officer of SciSparc.
  • “All our clinical and pre-clinical studies performed to date, in numerous diseases and conditions, indicated CannAmide™ ability to reduce doses while maintaining therapeutic efficacy and while increasing safety.

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv

Retrieved on: 
Tuesday, February 14, 2023
Therapy, CWY, Down, Greenberg Traurig, IPO, Capital market, FSE, CSE, Security (finance)

Tel Aviv, Israel / Vancouver, Canada, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it will present at the 2023 OurCrowd Global Investor Summit, that will take place on the 15th of February 2023, in Jerusalem, Israel.

Key Points: 
  • Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm
    Tel Aviv, Israel / Vancouver, Canada, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it will present at the 2023 OurCrowd Global Investor Summit , that will take place on the 15th of February 2023, in Jerusalem, Israel.
  • Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer, to present the company and share it experience from recent Nasdaq IPO.
  • The presentation will be part of special session sponsored by leading international law firm, Greenberg Traurig , hosted by shareholder at the firm, Mr. David Huberman.
  • The session will focus on “IPOs in a Down Market” and will take place at 12:00 PM at the GT Lounge, Room 314.

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Retrieved on: 
Wednesday, February 8, 2023
Obesity, FSE, Hebrew language, Metabolic syndrome, CWY, Drug development, Therapy, Metabolism, MEAI, Business development, CSE, Associate, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Tuesday, February 28th, at 8:30 AM EST.

Key Points: 
  • Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
  • The study was led by Professor Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.
  • Professor Tam will headline the conference discussing the challenges of obesity and the promising pre-clinical results for MEAI as a potential treatment.
  • The conference will also feature Mark Haden, Clearmind's VP of Business Development, and will be hosted by Shannon Smadella of Clearmind’s Community Development department.

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Retrieved on: 
Tuesday, January 31, 2023
FSL, Bar-Ilan University, Gonda, FSE, MDD, CWY, Therapy, United States Patent and Trademark Office, IP, Depression, Patient, CSE, Patent, Flinders, Major depressive disorder, Pharmaceutical industry, Ketamine

The trial evaluated 2-Fluorodeschloroketamine’s (“2-FDCK”), an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its use in treating depression including treatment resistant depression.

Key Points: 
  • The trial evaluated 2-Fluorodeschloroketamine’s (“2-FDCK”), an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its use in treating depression including treatment resistant depression.
  • In the trial, the Flinders Sensitive Line (“FSL”) rat, an animal model of depression, were treated either by Ketamine or 2-FDCK for 14 consecutive days.
  • The results indicated high potential safely treating both acute and chronic depression, compared to Ketamine that is used today for treating depression.
  • Our strong IP portfolio, includes numerous innovative compounds in the field of psychedelic-derived therapeutics," said Clearmind's CEO Dr. Adi Zuloff-Shani.

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Retrieved on: 
Wednesday, January 25, 2023
Psychoactive drug, Annual general meeting, Obesity, Hebrew University of Jerusalem, FSE, Hebrew language, Metabolic syndrome, CWY, Drug development, Therapy, MEAI, Eleazar Sukenik, CSE, Associate, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest results at Isranalytica 2023.

Key Points: 
  • The presentation, titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications," included data from recently announced pre-clinical results demonstrating efficacy of Clearmind’s drug candidate MEAI for treating obesity and metabolic syndrome.
  • Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, ranks as one of the world’s largest annual analytical chemistry conferences.
  • Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and Metabolism Laboratory, and he is an Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.
  • Along with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as part of Clearmind’s robust collaboration with the Hebrew University and its technology transfer company Yissum .

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Retrieved on: 
Thursday, January 19, 2023
CWY, Eleazar Sukenik, CSE, FSE, Safety, Hebrew University of Jerusalem, Therapy, Patient, Patent, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of two R&D projects with leading scientists from multiple disciplines at the Hebrew University as part of a collaboration established with the university’s technology transfer company, Yissum.

Key Points: 
  • The work included alterations of different regions of known molecules, to potentially improve their binding capabilities to the 5HT2A receptor.
  • The final stage of this project utilized an animal model to assess a possible increase in safety and efficacy.
  • These results are proof of the fruitful collaboration between Clearmind and leading academic institutions, which we value and appreciate," said Clearmind's CEO, Dr. Adi Zuloff-Shani.
  • These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications.